BIO 300 Featured at the 2023 Military Health System Research Symposium
The presentation provided an overview of recent data from studies with BIO 300 for the prevention of acute radiation syndrome
MINNEAPOLIS--(BUSINESS WIRE)--Updates on the development of Humanetics Corporation’s (Humanetics) new drug candidate, BIO 300, were presented at the 2023 Military Health System Research Symposium (MHSRS), held August 14-17th. MHSRS is the U.S. Department of Defense’s (DOD) foremost scientific meeting focusing on the unique medical needs of Warfighters.
Professor Vijay K. Singh, Ph.D. from the Uniformed Services University of the Health Sciences and the Armed Forces Radiobiology Research Institute, presented data related to the development of BIO 300 as a medical countermeasure for acute radiation syndrome (ARS), also known as radiation sickness. BIO 300 is being developed for use by military personnel, first responders, and at-risk civilian populations to prevent the harmful and deadly effects of ARS. There is an urgent need for drugs like BIO 300, as no FDA-approved countermeasures provide prophylactic protection against ARS.
Data presented at this meeting demonstrated the protective effects of oral and injectable formulations of BIO 300 from ARS when administered prior to exposure to radiation. Professor Singh’s presentation highlighted the research on BIO 300 that has positioned it as the most advanced prophylactic medical countermeasures currently under development for ARS. Developing countermeasures that protect individuals, especially military personnel, against ARS is paramount considering the current geopolitical environment fueling the real and increasing threat of nuclear or radiological events.
The development of BIO 300 is based upon research initiated by the DOD, which has granted worldwide exclusive rights to Humanetics for the development of the drug as a medical countermeasure for lethal radiation exposure. Multiple formulations of BIO 300 have been developed to allow different routes of administration that collectively address the unique operational needs of military personnel and first responders. Both injectable and oral formulations are shelf-stable and can be self-administered prior to exposure. This contrasts with current FDA-approved radiation countermeasures that address the symptoms of ARS when administered to victims already exposed. These countermeasures have limitations for military applications, including their need for cold storage and subcutaneous or intramuscular administration within 24-48 hours of exposure.
In addition to its military applications, BIO 300 is being evaluated in phase 2 clinical trials to prevent normal tissue injury resulting from cancer radiotherapy and to reduce lung damage in COVID-19 long-haul patients.
The research presented was supported in part by grants from the US Department of Defense’s Congressionally Directed Medical Research Program. The views expressed herein are those of Humanetics Corporation and may not reflect the official policy or position of the Uniformed Services University, Department of the Army, Department of Defense, or the US Government.
About Humanetics Corporation
Humanetics is a clinical-stage pharmaceutical company engaged in the discovery, development, and commercialization of proprietary drugs to prevent severe tissue damage caused by exposure to radiation, viral infection, and other inflammatory diseases. For more information, visit www.humaneticscorp.com.
Ronald J. Zenk